Organoid Development in Cancer Genome Discovery

Overview

Journal Curr Opin Genet Dev

Publisher Elsevier

Specialties Biology
Genetics

Date 2015 Mar 22

PMID 25796043

Citations 37

Authors

Dong Gao

Yu Chen

Affiliations

Soon will be listed here.

Abstract

The tumor response to most therapeutic agents in cancer is highly unpredictable. Cancer models which can adequately represent tumor heterogeneity and predict in vivo drug sensitivity are intense areas of investigation. Cancer cell lines and patient-derived xenograft models are the most frequently used models in cancer research and anticancer drug screening. Recently, cancer 'organoid' culture conditions have been developed to establish in vitro growth of patient-derived samples at higher efficiency and they are very promising for large scale drug screening and fundamental cancer biology research. Here, we leverage our experience in prostate cancer to discuss the advantages and limitations of these cancer models and summarize the development of cancer organoid culture--a development which may provide a new path towards personalized medicine in the future.

Citing Articles

Novel organoid model in drug screening: Past, present, and future.

Nie X, Liang Z, Li K, Yu H, Huang Y, Ye L Liver Res. 2025; 5(2):72-78.

PMID: 39959346 PMC: 11791835. DOI: 10.1016/j.livres.2021.05.003.

Revolutionizing digestive system tumor organoids research: Exploring the potential of tumor organoids.

Xiu Z, Yang Q, Xie F, Han F, He W, Liao W J Tissue Eng. 2024; 15:20417314241255470.

PMID: 38808253 PMC: 11131411. DOI: 10.1177/20417314241255470.

Organoids: An Emerging Precision Medicine Model for Prostate Cancer Research.

Waseem M, Wang B Int J Mol Sci. 2024; 25(2).

PMID: 38256166 PMC: 10816550. DOI: 10.3390/ijms25021093.

Introduction of Androgen Receptor Targeting shRNA Inhibits Tumor Growth in Patient-Derived Prostate Cancer Xenografts.

Thomas P, Alinezhad S, Joshi A, Sweeney K, Tse B, Tevz G Curr Oncol. 2023; 30(11):9437-9447.

PMID: 37999103 PMC: 10670201. DOI: 10.3390/curroncol30110683.

3D cancer models: One step closer to human studies.

Manduca N, Maccafeo E, De Maria R, Sistigu A, Musella M Front Immunol. 2023; 14:1175503.

PMID: 37114038 PMC: 10126361. DOI: 10.3389/fimmu.2023.1175503.

References

Sato T, Stange D, Ferrante M, Vries R, van Es J, van den Brink S . Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. Gastroenterology. 2011; 141(5):1762-72. DOI: 10.1053/j.gastro.2011.07.050. View

Hidalgo M, Bruckheimer E, Rajeshkumar N, Garrido-Laguna I, de Oliveira E, Rubio-Viqueira B . A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther. 2011; 10(8):1311-6. PMC: 4629061. DOI: 10.1158/1535-7163.MCT-11-0233. View

Suga H, Kadoshima T, Minaguchi M, Ohgushi M, Soen M, Nakano T . Self-formation of functional adenohypophysis in three-dimensional culture. Nature. 2011; 480(7375):57-62. DOI: 10.1038/nature10637. View

Liu X, Ory V, Chapman S, Yuan H, Albanese C, Kallakury B . ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. Am J Pathol. 2011; 180(2):599-607. PMC: 3349876. DOI: 10.1016/j.ajpath.2011.10.036. View

Choi N, Zhang B, Zhang L, Ittmann M, Xin L . Adult murine prostate basal and luminal cells are self-sustained lineages that can both serve as targets for prostate cancer initiation. Cancer Cell. 2012; 21(2):253-65. PMC: 3285423. DOI: 10.1016/j.ccr.2012.01.005. View

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E . Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13(3):239-46. DOI: 10.1016/S1470-2045(11)70393-X. View

Garnett M, Edelman E, Heidorn S, Greenman C, Dastur A, Lau K . Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 2012; 483(7391):570-5. PMC: 3349233. DOI: 10.1038/nature11005. View

Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin A, Kim S . The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012; 483(7391):603-7. PMC: 3320027. DOI: 10.1038/nature11003. View

Tentler J, Tan A, Weekes C, Jimeno A, Leong S, Pitts T . Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol. 2012; 9(6):338-50. PMC: 3928688. DOI: 10.1038/nrclinonc.2012.61. View

10.

Grasso C, Wu Y, Robinson D, Cao X, Dhanasekaran S, Khan A . The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012; 487(7406):239-43. PMC: 3396711. DOI: 10.1038/nature11125. View

11.

Yuan H, Myers S, Wang J, Zhou D, Woo J, Kallakury B . Use of reprogrammed cells to identify therapy for respiratory papillomatosis. N Engl J Med. 2012; 367(13):1220-7. PMC: 4030597. DOI: 10.1056/NEJMoa1203055. View

12.

Antonica F, Kasprzyk D, Opitz R, Iacovino M, Liao X, Dumitrescu A . Generation of functional thyroid from embryonic stem cells. Nature. 2012; 491(7422):66-71. PMC: 3687105. DOI: 10.1038/nature11525. View

13.

Huch M, Dorrell C, Boj S, van Es J, Li V, van de Wetering M . In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration. Nature. 2013; 494(7436):247-50. PMC: 3634804. DOI: 10.1038/nature11826. View

14.

Ozkumur E, Shah A, Ciciliano J, Emmink B, Miyamoto D, Brachtel E . Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med. 2013; 5(179):179ra47. PMC: 3760275. DOI: 10.1126/scitranslmed.3005616. View

15.

Lawrence M, Taylor R, Toivanen R, Pedersen J, Norden S, Pook D . A preclinical xenograft model of prostate cancer using human tumors. Nat Protoc. 2013; 8(5):836-48. DOI: 10.1038/nprot.2013.043. View

16.

Shaw A, Kim D, Nakagawa K, Seto T, Crino L, Ahn M . Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013; 368(25):2385-94. DOI: 10.1056/NEJMoa1214886. View

17.

De Mattos-Arruda L, Cortes J, Santarpia L, Vivancos A, Tabernero J, Reis-Filho J . Circulating tumour cells and cell-free DNA as tools for managing breast cancer. Nat Rev Clin Oncol. 2013; 10(7):377-89. DOI: 10.1038/nrclinonc.2013.80. View

18.

Koehler K, Mikosz A, Molosh A, Patel D, Hashino E . Generation of inner ear sensory epithelia from pluripotent stem cells in 3D culture. Nature. 2013; 500(7461):217-21. PMC: 3739998. DOI: 10.1038/nature12298. View

19.

Sequist L, Yang J, Yamamoto N, OByrne K, Hirsh V, Mok T . Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013; 31(27):3327-34. DOI: 10.1200/JCO.2012.44.2806. View

20.

Lancaster M, Renner M, Martin C, Wenzel D, Bicknell L, Hurles M . Cerebral organoids model human brain development and microcephaly. Nature. 2013; 501(7467):373-9. PMC: 3817409. DOI: 10.1038/nature12517. View